Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications

Size: px
Start display at page:

Download "Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications"

Transcription

1 Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications Arja Jukkola, Risto Bloigu 1, Tapani Ebeling 2, Pasi Salmela 2 and Guillermo Blanco Department of Oncology, Oulu University Hospital, Finland 1 Department of Medical Informatics, Oulu University Hospital, Finland 2 Department of Internal Medicine, Oulu University Hospital, Finland (Requests for offprints should be addressed to G Blanco, Department of Clinical Oncology, Oulu University Hospital, PL 22, FIN Oulu, Finland; guillermo.blanco@ppsph.fi) Abstract Differentiated thyroid carcinomas (DTC) (papillary, follicular and follicular type of papillary) have a favourable prognosis, but a proportion of patients develop recurrences and eventually die of the disease. Various prognostic factors have been identified and been used to create the current staging classifications (AGES, AMES, MACIS, EORTC, UICC-TNM). We examined 499 DTC patients retrospectively to validate known prognostic factors that enable them to be recognised as having either a low or a high risk of death related to a recurrence of DTC, by reference to the current staging classifications. Sixty-nine of them (14%) had local or distant recurrences, the mean time to recurrence being 7.7 years. The 10-year disease-free survival rate was 80%, and the ten-year overall survival rate for the entire group was 91%, with a mean survival time of 8.7 years. Male gender, a follicular type of tumour, larger tumour size, extrathyroidal invasion outside the capsule and nodal metastases were all related to a higher incidence of tumour recurrence, and the follicular type of histology, age > 45 years, larger tumour size and local invasion entailed poorer survival. The AMES and to some extent the EORTC classification were not reproducible in this material, mainly because some prognostic variants were no longer encountered or were insufficient in number to allow reliable conclusions to be drawn. The MACIS staging classification leaves the definition of the intermediate and high risk groups too wide and is therefore not very reliable. Pooling of stages I and II improved the relevance of the TNM classification. All the current staging classifications are able to discern a low risk DTC group well. We achieved a highly accurate definition of risk in the present material using only two parameters, age (cut-off value 50 years) and extracapsular invasion of the thyroid gland. Endocrine-Related Cancer (2004) Introduction The incidence of thyroid carcinoma in Finland has been steadily rising so that, according to the Finnish Cancer Registry (2003), there were 303 new cases in 2001, representing 1.3% of all new cancers recorded in that year and implying a twofold increase for men and an increase of approximately 30% for women during the last decade. Thyroid carcinoma is almost four times as frequent in females as in males in Finland, 6.6/ compared with only 2.1/ in men (Finnish Cancer Registry 2003). Papillary and follicular thyroid carcinoma, referred to as differentiated thyroid carcinoma (DTC) cover the majority of thyroid carcinoma cases. The prognosis for DTC is usually excellent, but even so a proportion of the patients develop recurrences and eventually die of the disease. Age at the time of diagnosis, gender, histological type, tumour size and extrathyroidal invasion have been found previously to be associated with a poor clinical outcome (Cady & Rossi 1988, De Groot et al. 1990, Hay 1990, Schlumberger & Pacini 1999), while the prognostic impact of regional lymph node metasases is still a Endocrine-Related Cancer (2004) /04/ # 2004 Society for Endocrinology Printed in Great Britain DOI: /erc

2 Jukkola et al.: Prognostic factors in differentiated thyroid carcinomas controversial issue (Cady & Rossi 1988, De Groot et al. 1990, Frankenthaler et al. 1990, Akslen et al. 1991, Sellers et al. 1992). The presence of distant metastases at the time of diagnosis is a recognised factor for a poor prognosis (Cady et al. 1979, Hay 1990). The predictability of the outcome is closely related to these risk factors, which have been used to develop various prognostic staging systems to discern patients with either a low or a high risk of recurrence or DTCrelated death. Many scoring or staging systems have been developed for this purpose during the last two decades, but up to now there has been no consensus regarding the clinical relevance of any one staging classification rather than the others. The most commonly used staging classifications are AMES (Cady & Rossi 1988), AGES (Hay et al. 1987), MACIS (Hay et al. 1993), EORTC (Byar et al. 1979), and UICC-TNM (Hermanek & Sobin 1992). These use well-defined prognostic factor values that enable the construction of scores, which in turn can be used to give accurate predictions of the long-term outcome for individual patients. The clinical applicability of these staging classifications for patients with DTC has certain limitations, mainly because they do not reflect the actual clinical presentation of patients with DTC, nor do they consider the impact of early diagnosis and therapy on the outcome of DTC. This study examines retrospectively 499 cases with DTC treated at our institution during the years to define more closely the prognostic factors that were related to a poor clinical outcome and to look for a staging classification which will not only facilitate treatment decisions but will also provide a reliable method for comparing results between centres. Patients and methods Patients The patient characteristics are described in Table 1. Four hundred and ninety-nine cases of well differentiated thyroid carcinoma (DTC), 366 (73%) of the papillary type, 47 (10%) of the follicular type and 86 (17%) of the follicular papillary type (Table 1), treated in Northern Finland during the years , were analysed in this retrospective study. The average population of the Oulu and Lapland regions together is about The majority of the patients were women (82%) (Table 1), and the mean age was 47 years (range 14 86). The mean age of the patients with papillary carcinoma was 46 years (range 14 86), that of the follicular carcinoma group was 50 years (range 19 83), while that of the patients with the follicular variant of papillary carcinoma was the lowest, 45 years (range 15 75). The highest incidence of DTC was at years in the females and at years in the Table 1 Patient characteristics. Factor Patients n % Gender ðn ¼ 499Þ Female 408 (82) Male 91 (18) Histology ðn ¼ 499Þ Papillary 366 (73) Follicular 47 (10) Follicular type of papillary 86 (17) Surgery ðn ¼ 486Þ Total thyroidectomy 426 (87) Lobectomy 17 (4) Subtotal thyroidectomy 43 (9) Tumour size ðn ¼ 408Þ T1; <1 cm 105 (25) T2; 1 4 cm 284 (70) T3; > 4 cm 19 (5) Nodal status ðn ¼ 408Þ N 418 (90) Nþ 48 (10) Capsule infiltration ðn ¼ 404Þ No 185 (46) Yes 118 (30) Outside the capsule 101 (24) Lymph vessel infiltration ðn ¼ 456Þ No 400 (87) Yes 56 (13) Blood vessel infiltration ðn ¼ 459Þ No 419 (91) Yes 40 (9) Muscle infiltration ðn ¼ 459Þ No 417 (91) Yes 42 (9) Primary site of metastases ðn ¼ 492Þ No 425 (86) Lung 9 (2) Nodule 55 (11) Blood vessel 2 (0.6) Multiple 1 (0.4) Radiotherapy ðn ¼ 499Þ No 484 (97) Yes 15 (3) males. The mean follow-up time was 8.7 years (range ). Hashimoto s thyroiditis was found in 18% of the patients and struma nodosa in 33%. Achieved Basedow disease occurred only in 0.3%. Other cancers developed in 3.2% of the cases, but were restricted entirely to those patients with the papillary type. In 4% of the cases with papillary carcinoma, DTC was also found among close relatives. An overwhelming majority of the tumours were classified as T1 (<1 cm) or T2 (1 4 cm) (95%) (Table 1), representing 96% of the cases in the papillary group, 81% 572

3 in the follicular group and 99% in the follicular variant of papillary thyroid carcinoma. The proportion of tumours less than 1 cm was uneven, being 28% in the papillary group, but only 3% in the follicular group, while the proportion in the group with the follicular variant of papillary carcinoma was quite similar to that in the papillary group, 25%. Attachment to the thyroid capsule was detected in a quarter of the patients, and infiltration through the capsule occurred in 24%. Invasion of the extracellular tissue was found in the lymph vessels (13%), muscle (9%) or blood vessels (9%). The main metastatic site was the regional lymph nodes (11%) (Table 1). Incidental tumours were recognised in approximately 8% of the cases undergoing thyroidectomy for reasons other than carcinoma. Total thyroidectomy and iodine-131 ablation treatment to destroy the thyroid remnant was the main therapy used in this population. Patients with nodal metastases in the neck region, as determined by ultrasound and needle biopsy or during operation, underwent neck surgery. Serum thyroglobulin and thyrotrophin (TSH) concentrations (intended suppressed values TSH 0.05 mu/l) were measured during the follow-up. Total thyroidectomy was performed on 426 of the surgical patients (87%), subtotal thyroidectomy in 43 cases (9%) and lobectomy in 17 cases (4%) respectively. Only 4 patients (1%) were considered inoperable. No data were available on 9 patients. Only 62 patients (12%) underwent neck surgery. Ninety-two percent of the patients showed thyroid tissue remnants after scanning with 5 mci iodine-131 after surgery, but only in 1% was there iodine positivity outside the neck region. The patients exhibiting thyroid tissue remnants were treated with iodine-131 ablation of 100 mci if they had negative lymph nodes, or of 150 mci if the lymph nodes were positive for malignancy. In almost half of the cases, two ablative procedures were required to destroy the remaining thyroid tissue. In 4% of the patients, external radiotherapy to the neck region was used because of inoperable local disease or because of iodine-131 negativity in the thyroid remnant or in lymph nodes in the neck region that were positive for malignancy. Mild transient hypocalcaemia was found in 134 patients after surgery, and 13% of them needed calcium substitution. Unilateral recurrent laryngeal nerve palsy was detected in 3.5% of the cases and bilateral recurrent laryngeal nerve palsy in five cases. The study proposal was approved by the Ethical Committee of the Faculty of Medicine, University of Oulu and Oulu University Hospital, and the Finnish Ministry of Health gave permission for the further use of patients tissue samples. Statistical analyses Standard tests of statistical significance were used: Student s t-test, Mann Whitney, Pearson and Chi- Square. Survival curves (Kaplan Meier) were compared using the log rank, Breslow or Tartone Ware test. P < 0:05 was considered statistically significant. Cox regression analysis was used to find significant predictors of survival in the different staging classifications. The proportion of deaths due to thyroid carcinoma was too low to create a reliable multivariate analysis. Results Validation of predictors of DTC recurrence Sixty-nine patients out of the 499 had local or distant recurrences (14%), the average time to recurrence being 7.7 years. The 10-year disease-free survival rate in the whole group was 80%. Gender predicted the recurrence of DTC ðp ¼ 0:003Þ, males having a poorer prognosis than females (Table 2), but age at onset did not predict recurrence ðp ¼ 0:6Þ. The follicular type of tumour entailed a higher risk of recurrence ðp ¼ 0:01Þ. The majority of the patients (70%) had tumours <1 4 cm (T2) in diameter, and larger tumours carried a higher risk of recurrence ðp ¼ 0:0001Þ. Local invasion, in the form of capsule invasion ðp ¼ 0:0001Þ, lymph vessel invasion ðp ¼ 0:0001Þ, blood vessel invasion ðp ¼ 0:03Þ and muscle invasion ðp ¼ 0:0001Þ, was also found to be associated with a higher incidence of tumour recurrence, but this was not the case with attachment of the tumour to the thyroid capsule alone. The 14 patients with nodal metastases had a significantly shorter recurrence-free survival than those without nodal disease ðp ¼ 0:0001Þ (Table 2). Four hundred and twenty-six patients underwent total thyroidectomy and the rest underwent either hemitotal thyroidectomy or subtotal resection, with the exception of four patients who had an inoperable disease. The patients treated with total thyroidectomy had a significantly better recurrence-free survival rate than the other surgical cases ðp ¼ 0:03Þ, but the patients on whom neck surgery was performed for primary nodal metastases ðp ¼ 0:0001Þ and those who received radiotherapy to the neck region had poorer recurrence-free survival rates ðp ¼ 0:007Þ (Table 2). Validation of factors for overall survival The 5-year overall survival rate for the entire DTC group was 95%, and the 10-year survival rate was 91%. The mean survival time was 8.7 years. In the univariate analysis the follicular type of histology ðp ¼ 0:01Þ, age > 45 years ðp ¼ 0:0001Þ, larger tumour size ðp ¼ 0:0001Þ and local invasion, i.e. invasion beyond the capsule ðp ¼ 0:0001Þ, lymph vessel invasion ðp ¼ 0:008Þ, blood 573

4 Jukkola et al.: Prognostic factors in differentiated thyroid carcinomas Table 2 Characteristics of the population in terms of the recurrence (REC) of differentiated thyroid carcinoma and overall survival (OS). Numbers (n) and percentages of patients are given (%). REC RECþ OS n (%) n (%) P-value a P-value a Gender Male 70 (77) 21 (23) female 360 (88) 48 (12) Age years 204 (86) 32 (14) > 45 years 226 (86) 37 (14) Histology Papillary 313 (86) 53 (14) Follicular 35 (75) 12 (25) Follicular type of papillary 82 (95) 4 (5) Tumour size T1 98 (94) 7 (6) T2 253 (89) 31 (11) T3 11 (58) 8 (42) Nodal metastases N 376 (90) 42 (10) Nþ 34 (71) 14 (29) Capsule infiltration No 174 (94) 11 (6) Yes 110 (93) 8 (7) Outside the capsule 73 (72) 28 (28) Lymph vessel infiltration No 365 (91) 35 (9) Yes 38 (67) 19 (33) Blood vessel infiltration No 376 (90) 43 (10) Yes 31 (77) 9 (23) Muscle infiltration No 377 (90) 40 (10) Yes 29 (69) 13 (31) Distant metastases MO 381 (90) 44 (10) M1þ 5 (40) 7 (60) Surgery Total thyroidectomy 417 (98) 9 (2) Lobectomy 15 (65) 2 (25) Subtotal thyroidectomy 39 (90) 4 (10) Neck surgery No 389 (89) 45 (11) Yes 40 (64) 22 (36) Radiotherapy No 420 (87) 64 (13) Yes 10 (67) 5 (33) a log-rank. vessel ðp ¼ 0:0007Þ and muscle ðp ¼ 0:0001Þ infiltration entailed a shorter survival. Patients treated with total thyroidectomy had a better prognosis, as did those who did not receive radiotherapy. The patients with primary distant metastases had a poor survival outcome. Gender, presence of nodal metastases or neck surgery did not affect survival (Table 2). The AMES classification The first report from the Lahey Clinic Foundation (Cady et al. 1979) used three prognostic factors for the analysis of risk in cases of DTC, namely age (cut-off 40 years for men and 50 years for women), gender and histological type: follicular vs papillary. Applying the same prognostic factors as stated in the first publication of the AMES 574

5 Figure 1 Overall survival, determined by Kaplan Meier analysis, in terms of (A) the AMES classification: dotted line, low risk ðn ¼ 280Þ; dashed line, intermediate risk ðn ¼ 189Þ; solid line, high risk ðn ¼ 29Þ; (B) the MACIS performance score classification: dashed line, ðn ¼ 419Þ; solid line, ðn ¼ 43Þ; dotted line, ðn ¼ 20Þ; dotted/dashed line, 9þ ðn ¼ 16Þ; (C) the TNM classification (patients 45 years): dashed line, stage I ðn ¼ 99Þ; solid line, stage II ðn ¼ 106Þ; dotted line, stage III ðn ¼ 8Þ; dotted/dashed line, stage IV ðn ¼ 11Þ; (D) extracapsular invasion and age: dashed line, low risk (age <50 years without extracapsular invasion) ðn ¼ 450Þ; solid line, high risk (age 50 years and extracapsular invasion) ðn ¼ 48Þ. staging classification (Cady et al. 1979) to this present population, it was possible to discern a low-risk group with a survival rate of 100% at 20 years, an intermediaterisk group with a survival rate of 84% and a high-risk group with a survival rate of 54% (Fig. 1A). The second report from the same institution (Cady & Rossi 1988) added two further parameters that were important for the prognosis: the size of the tumour and the local and distant extents of the disease, thus achieving a more accurate prognosis and distinguishing a low-risk group and a high- 575

6 Jukkola et al.: Prognostic factors in differentiated thyroid carcinomas risk group. Unfortunately, the addition of a tumour size over 5 cm and the presence of distant metastases, requirements for the elaboration of the expanded risk definition as stated in the second AMES staging classification (Cady & Rossi 1988), were not applicable to our population, so that it was not possible to reproduce this classification, which had to be disregarded. The MACIS scoring classification This classification used standard survival analysis to estimate the percentage of patients surviving DTC at specific times after the initial treatment, together with a comparison of survival curves and a multivariate analysis to define the variables examined as possible predictors of DTC survival (Hay et al. 1993). After validation of many of the prognostic variables in a set of patients, five variables emerged as useful predictors of survival: age (cut-off 40 years), size of the tumour, incomplete operation, extrathyroidal invasion and distant metastases. These variables were used to construct a system for assigning performance scores and defining four prognostic groups (0 6.9, , , 9.0þ), with an accurate DTC mortality rate for each at 20 years of follow-up. When our population was assessed according to these variables and the scoring system used to create the MACIS staging classification, four risk groups emerged: a low-risk group (score 0 6.9) with a survival rate of 94% at 20 years, a high-risk group (9þ) with a survival rate of 58%, and two other risk groups (7-7.9 and 8-8.9) that lay in between but had less clear, superimposed survival curves, both with a survival rate of 83% (Fig. 1B). The TNM classification The TNM classification is a good attempt at conciliating and unifying thyroid carcinoma with the International Classification Guide for Tumours (Hermanek & Sobin 1992). This classification integrates all histological variants of thyroid carcinoma, but a separate stage group for papillary and follicular carcinoma together is recommended. It takes into account age (cut-off 45 years), size of the tumour, nodal involvement and distant metastases. The staging classification defines the low-risk group well in our population, with a survival rate of 100% at 20 years (stage I), and also distinguishes the highest risk group (stage IV), as expected, as it has no survivors after the same length of time, but again the intermediate-risk groups are less well defined (stage II and stage III), with survival curves that are superimposed and represent survival rates of 74% and 85% respectively at 20 years (Fig. 1C). No deaths were detected in patients <45 years, which is why these patients are not included in Fig. IC. A proposal for risk definition - age and extracapsular involvement By taking into account two relevant factors defined by univariate analysis in the present material, age (<50 years and 50 years) and extracapsular involvement, as the sole prognostic variables for discerning low-risk and high-risk categories it was indeed possible in a very simple way to recognise a low-risk category with a survival rate of 89% at 20 years and a high-risk category with a survival rate of 60% (Fig. 1D). Comparisons of the factors used in these staging classifications and the Cox regression analysis for the risk of death in relation to the classifications are presented in Tables 3 and 4 respectively. Discussion In general, DTC has a favourable prognosis, but it is of great importance to identify at the time of diagnosis those patients who have a high risk of progressive disease and DTC-related death. The importance of recognising prognostic variables is also relevant for the optimal management of DTC, e.g. the extent of thyroid surgery and the indications for postoperative radioiodine therapy. A recognised prognostic classification is also critical for the comparison of treatment results. Gender proved here to be of prognostic value for disease-free survival, which was shorter for males than for females. Our patients older than 45 years also had a poorer disease outcome, but advanced age did not predict shorter recurrence-free survival (Table 2). Gender has been found to be an independent prognostic factor (Cunningham et al. 1990), but controversial results have also been published (Gilliland et al. 1997). Earlier studies have shown than the prognosis is poor in older patients with DTC (Rigway 1992, Schlumberger & Pacini 1999). Lymph node metastases were a risk factor for recurrence, and they were most numerous in the papillary type of carcinoma (Table 2), as described earlier (Mazzaferri & Jhiang 1994, Sclumberger 1998). In some, but not all, studies (Hay 1990, Mazzaferri & Jhiang 1994), local lymph node involvement has been associated with an increased risk of tumour recurrence and also with DTC-related mortality (Mazzaferri & Jhiang 1981, Mizukami et al. 1992, Schlumberger & Pacini 1999). The prognostic impact of regional lymph node metastases still remains a controversial issue. The presence of primary distant metastases beyond the neck entails a poorer prognosis, and patients treated with radiotherapy to the neck region at the time of diagnosis also have a poor prognosis (Table 2). The accuracy of the preoperative diagnosis of thyroid malignancy has substantially improved over the years, thanks to the combined use of ultrasound and fine needle biopsy, and this has markedly influenced the recognition 576

7 Table 3 Comparison of the factors used in three staging classifications and in the new proposal from this paper. TNM a MACIS b AMES c New proposal Histology Papillary Same Same Same Follicular Follicular type of papillary Age <45 years/45 years Continuous <40 years/> 40 years male <50 years/50 years <50 years/> 50 years female Gender No No Yes No Size (in cm) <1 Continuous No No 1 4 > 4 Extracapsular invasion No Yes No Yes Residual disease No Yes No No Lymph nodes Yes No No No Metastases Yes Yes No No a Hermanek & Sobin (1992); b Hat et al. (1993); c Cady et al. (1979). of malignancy at earlier stages (Mäka ra inen 1986). The change towards earlier diagnosis may have implications for the use of the current staging classifications. Here, we set out to explore the predictability of the outcome by using defined valid prognostic variables applied to the current staging classifications, which in general serve well to define prognostic groups, although the applicability of these classifications to the present DTC material is less reliable, especially with regard to the definition groups with a high and an intermediate risk of DTC-related death. It has been suggested that one of the criteria for a good staging system is that the survival curves for the stage groups are well separated (Hannequin et al. 1986, Brierley et al. 1997). When the prognostic factors in this population are assessed in terms of the first AMES classification (Cady et al. 1979), it is possible to discern three risk groups - low, intermediate and high (Fig. 1A, Table 3). The extended AMES staging classification which takes into account tumour size and the extent of the disease (Cady & Rossi 1988) was not reproducible in this material, mainly because some prognostic variants were no longer encountered or the numbers were insufficient to allow reliable conclusions to be drawn. We also had difficulties in reproducing the results when using the EORTC or AGES classifications. EORTC yields five risk groups based on age, gender, cell type, presence of anaplastic carcinoma, tumour size and Table 4 Risk of death in cases of well-differentiated thyroid carcinoma according to the various classification systems in multivariate Cox regression analysis. Classification No. of patients Risk of death odds ratio (95% confidence interval) P-value TNM 411 Stage I and II Stage III ( ) Stage IV (23 298) AMES 498 Low Intermediate ( ) 0/002 High ( ) MACIS (1.1 11) (1.9 26) þ (8.3 78) Extracapsular invasion and age 498 Low High (4.8 27)

8 Jukkola et al.: Prognostic factors in differentiated thyroid carcinomas number of metastatic sites expressed in terms of individual scores which distinguish survival curves (Byar et al. 1979), but because of the difficulties in matching the variables used in this classification, it was also disregarded. Four risk groups emerged in our population when we used the MACIS classification (Table 3, Fig. 1B). This staging classification uses prognostic scores to create intermediate risk groups, albeit with statistical significance but too close to each other, making the definition of the intermediate-risk group too broad and not very reliable. The TNM classification meets with the same difficulties. This defines the low-risk group (stage I) and the highrisk group (stage IV) well in our population, but not the intermediate-risk group (stages II and III) (Table 3, Fig. 1C). The only prognostic variable for patients aged under 45 years is the presence or absence of distant metastases, whereas for those over 45 years of age the classification relies on the size of the tumour, extension of the disease to the lymph nodes and the presence of distant metastases. The risk of recurrence may be underestimated in young patients because they are classified as having stage I disease in the absence of distant metastases even in the presence of locally aggressive tumours. The new 2002 proposal differs substantially from the 1992 classification, the main differences being related to extrathyroidal extension of the disease, nodal involvement and, to some extent, tumour size. The clinical application of the new proposal could only be tested in a prospective study. The use of only two parameters, age (<50 years and 50 years) and extracapsular invasion of the thyroid gland, allowed us to achieve an appropriate and easy definition of risk in this set of patients (Table 3, Fig. 1D). A very close attempt to ours has been made at the Institute Gustave-Roussy (the IGR classification), where a highly significant definition of risk in DTC was obtained using only age and malignancy grade (Schlumberger & Pacini 1999). Although all the current classifications are able to discern a low-risk group with an excellent prognosis, early diagnosis means that many prognostic variables are no longer found in our population, making the predictability of the traditional staging classifications less accurate today than at the time when they were developed. Brierley et al. (1997) have reported for a population representing the years that there was no difference in the abilities of the top five classifications (AGES, TNM, EORTC, MACIS and AMES) to predict the prognosis for patients with differentiated thyroid carcinoma, and no statistically significant superiority of any system over the TNM classification was found. A staging classification needs to identify patients for whom there is a high risk of failure. Most differentiated thyroid carcinoma patients nowadays have a stage I II disease and the proportion of high-risk patients is expected to be small. The differences in patient distribution between the staging classifications reflect problems in applying a classification developed for one population to another (Brierley et al. 1997). The majority of the patients presented here could be defined as having a low risk of recurrence or of DTCrelated death, a finding that raises another important question: the need to avoid overtreating low-risk DTC patients and to consider the use of less radical procedures. References Akslen LA, Haldorsen T & Thoresen SO 1991 Survival and causes of death in thyroid cancer: a population-based study of 2479 cases from Norway. Cancer Research Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK & O Sullivan B 1997 A comparison of different staging systems predictability of patient outcome. Cancer Byar DP, Green SB, Dor P, Williams ED, Colon J, van Gilse HA, Mayer M, Sylvester RJ & van Glabbeke M 1979 A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. European Journal of Cancer Cady B & Rossi R 1988 An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery Cady B, Sedgwick MD, Meissner WA, Wool MS, Salzman FA & Werber J 1979 Risk factor analysis in differentiated thyroid cancer. Cancer Cunningham MP, Dupa RB, Recant W, Chmiel JS, Sylvester JA & Fremgen A 1990 Survival discriminants for differentiated thyroid cancer. American Journal of Surgery De Groot LJ, Kaplan EL, McCormick M & Straus F 1990 Natural history, treatment, and course of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism Finnish Cancer Registry 2003 Cancer incidence in Finland 2000 and In Finnish Cancer Registry. Institute for Statistical and Epidemiological Cancer Research. Frankenthaler RA, Sellin RV, Cangir A & Goepfert H 1990 Lymph node metastasis from papillary-follicular thyroid carcinoma in young patients. American Journal of Surgery Gilliland FD, Hunt WC, Morris DM & Key CR 1997 Prognostic factors for thyroid carcinoma. Population-based study of cases from Surveillance, Epidemiology and End results (SEER) program Cancer Hannequin P, Liehn JC & Delisle MJ 1986 Multifactorial analysis of survival in thyroid cancer: pitfalls of applying the results of published studies to another population. Cancer Hay ID 1990 Papillary thyroid carcinoma. Endocrinology and Metabolism Clinics of North America Hay ID, Grant CS, Taylor WF & McConahey WM 1987 Ipsilateral lobectomy versus bilateral lobar resection in 578

9 papillary carcinoma: a reprospective analysis of surgical outcome using a novel prognostic scoring system. Surgery Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR & Grant CS 1993 Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1997 patients surgically treated at one institution during 1940 through Surgery Hermanek P & Sobin LH 1992 Thyroid gland (ICD-OC73). In TNM Classification of Malignant Tumors, edn 4, pp Eds P Hermanek & LH Sobin. Berlin: Springer-Verlag. Mäkäräinen H 1986 Preoperative ultrasound of the thyroid combined with fine needle biopsy. In Acta Universitas Ouluensis. Oulu University Press: Oulu, Finland. Mazzaferri EL & Young EL 1981 Papillarythyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. American Journal of Medicine Mazzaferri EL & Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American Journal of Medicine Mizukami Y, Noguchi M, Michigishi T, Nomomura A, Hashimato T, Otakes S, Nakamura S & Matsubara F 1992 Papillary thyroid carcinoma in Kanazawa, Japan: prognostic significance of histological subtypes. Histopathology Rigway EC 1992 Clinical review 30: clinician s evaluation of a solitary thyroid nodule. Journal of Clinical Endocrinology and Metabolism Schlumberger MJ 1998 Papillary and follicular thyroid carcinoma. New England Journal of Medicine Schlumberger M & Pacini P 1999 Differentiated thyroid carcinoma. In Thyroid Tumor, edn, pp Nucleon: Paris. Sellers M, Beenken S, Blankenship A, Soong SJ, Turbat-Herrera E, Urist M & Maddox W 1992 Prognostic significance of cervical lymph node metastases in differentiated thyroid cancer. American Journal of Surgery

PAPER. Predicting Outcome and Directing Therapy for Papillary Thyroid Carcinoma

PAPER. Predicting Outcome and Directing Therapy for Papillary Thyroid Carcinoma PAPER Predicting Outcome and Directing Therapy for Papillary Thyroid Carcinoma Sendia Kim, MD; John P. Wei, MD; Joshua M. Braveman, MD; David M. Brams, MD Hypothesis: The prognosis of papillary thyroid

More information

ORIGINAL ARTICLE. Indications for Bilateral Modified Radical Neck Dissection in Patients With Papillary Carcinoma of the Thyroid

ORIGINAL ARTICLE. Indications for Bilateral Modified Radical Neck Dissection in Patients With Papillary Carcinoma of the Thyroid ORIGINAL ARTICLE Indications for Bilateral Modified Radical Neck Dissection in Patients With Papillary Carcinoma of the Thyroid Akira Ohshima, MD, PhD; Hiroyuki Yamashita, MD, PhD; Shiro Noguchi, MD, PhD;

More information

ORIGINAL ARTICLE. Changing Trends and Prognoses for Patients With Papillary Thyroid Cancer

ORIGINAL ARTICLE. Changing Trends and Prognoses for Patients With Papillary Thyroid Cancer ORIGINAL ARTICLE Changing Trends and Prognoses for Patients With Papillary Thyroid Cancer Hiroyuki Yamashita, MD, PhD; Shiro Noguchi, MD, PhD; Hiroto Yamashita, MD, PhD; Nobuo Murakami, MD; Shin Watanabe,

More information

Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules

Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA

More information

Prognostic Factors for Well Differentiated Thyroid Cancer in an Endemic Area

Prognostic Factors for Well Differentiated Thyroid Cancer in an Endemic Area Prognostic Factors for Well Differentiated Thyroid Cancer in an Endemic Area A retrospective analysis of 215 differentiated thyroid cancers was undertaken to identify the various prognostic variables.

More information

SARDA AND OTHERS No. of patients (%) Figure 1. Age distribution. Papillary Follicular < > 60 Age at chagnos

SARDA AND OTHERS No. of patients (%) Figure 1. Age distribution. Papillary Follicular < > 60 Age at chagnos Asian Journal of Surgery Excerpta Medica Asia Ltd Prognostic Factors for Well-Differentiated Thyroid Cancer in an Endemic Area A.K. Sarda, Shweta Aggarwal, Durgatosh Pandey, Gagan Gautam, Department of

More information

Management guideline for patients with differentiated thyroid cancer. Teeraporn Ratanaanekchai ENT, KKU 17 October 2007

Management guideline for patients with differentiated thyroid cancer. Teeraporn Ratanaanekchai ENT, KKU 17 October 2007 Management guideline for patients with differentiated thyroid Teeraporn Ratanaanekchai ENT, KKU 17 October 2007 Incidence (Srinagarind Hospital, 2005, both sex) Site (all) cases % 1. Liver 1178 27 2. Lung

More information

4/22/2010. Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey.

4/22/2010. Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey. Management of Differentiated Thyroid Cancer: Head Neck Surgeon Perspective Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey Thyroid gland Small endocrine gland:

More information

Adjuvant therapy for thyroid cancer

Adjuvant therapy for thyroid cancer Carcinoma of the thyroid Adjuvant therapy for thyroid cancer John Hay Department of Radiation Oncology Vancouver Cancer Centre Department of Surgery UBC 1% of all new malignancies 0.5% in men 1.5% in women

More information

Persistent & Recurrent Differentiated Thyroid Cancer

Persistent & Recurrent Differentiated Thyroid Cancer Persistent & Recurrent Differentiated Thyroid Cancer Electron Kebebew University of California, San Francisco Department of Surgery Objectives Risk factors for persistent & recurrent disease Causes of

More information

A variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study

A variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study ORIGINAL ARTICLE A variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study Joon-Hyop Lee, MD, Yoo Seung Chung, MD, PhD,* Young Don Lee, MD, PhD

More information

Gerard M. Doherty, MD

Gerard M. Doherty, MD Surgical Management of Differentiated Thyroid Cancer: Update on 2015 ATA Guidelines Gerard M. Doherty, MD Chair of Surgery Utley Professor of Surgery and Medicine Boston University Surgeon-in-Chief Boston

More information

Thyroid nodules - medical and surgical management. Endocrinology and Endocrine Surgery Manchester Royal Infirmary

Thyroid nodules - medical and surgical management. Endocrinology and Endocrine Surgery Manchester Royal Infirmary Thyroid nodules - medical and surgical management JRE Davis NR Parrott Endocrinology and Endocrine Surgery Manchester Royal Infirmary Thyroid nodules - prevalence Thyroid nodules common, increase with

More information

Differentiated Thyroid Cancer: Initial Management

Differentiated Thyroid Cancer: Initial Management Page 1 ATA HOME GIVE ONLINE ABOUT THE ATA JOIN THE ATA MEMBER SIGN-IN INFORMATION FOR PATIENTS FIND A THYROID SPECIALIST Home Management Guidelines for Patients with Thyroid Nodules and Differentiated

More information

Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan

Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan ORIGINAL ARTICLE Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan I. Hommel 1 *, G.F. Pieters 1, A.J.M. Rijnders 2, M.M. van Borren 3, H. de

More information

Thyroid Cancer: When to Treat? MEGAN R. HAYMART, MD

Thyroid Cancer: When to Treat? MEGAN R. HAYMART, MD Thyroid Cancer: When to Treat? MEGAN R. HAYMART, MD ASSOCIATE PROFESSOR OF MEDICINE UNIVERSITY OF MICHIGAN MICHIGAN AACE 2018 ANNUAL MEETING Thyroid Cancer: When Not to Treat? FOCUS WILL BE ON LOW-RISK

More information

Review Article Management of papillary and follicular (differentiated) thyroid carcinoma-an update

Review Article Management of papillary and follicular (differentiated) thyroid carcinoma-an update Bangladesh J Otorhinolaryngol 2010; 16(2): 126-130 Review Article Management of papillary and follicular (differentiated) thyroid carcinoma-an update Md. Abdul Mobin Choudhury 1, Md. Abdul Alim Shaikh

More information

Clinically Significant Prognostic Factors for Differentiated Thyroid Carcinoma

Clinically Significant Prognostic Factors for Differentiated Thyroid Carcinoma 524 Clinically Significant Prognostic Factors for Differentiated Thyroid Carcinoma A Population-Based, Nested Case Control Study Catharina Ihre Lundgren, M.D. 1,2 Per Hall, M.D., Ph.D. 1 Paul W. Dickman,

More information

Ultrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer

Ultrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer Ultrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer Its Not Just About the Nodes AACE Advances in Medical and Surgical Management of Thyroid Cancer - 2017 Robert A. Levine, MD,

More information

The International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology

The International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies

More information

Validity of risk group definition in

Validity of risk group definition in Validity of risk group definition in differentiated thyroid carcinoma J M G\l=o'\mez,N G\l=o'\mez,M Sah\l=u'\n, A Rafecas, C Villabona and J Soler Services of Endocrinology and Surgery, Ciudad Sanitaria

More information

10/24/2008. Surgery for Well-differentiated Thyroid Carcinoma- The Primary

10/24/2008. Surgery for Well-differentiated Thyroid Carcinoma- The Primary Surgery for Well-differentiated Thyroid Carcinoma- The Primary Head and Neck Endocrine Surgery Department of Otolaryngology-Head and Neck Surgery, UCSF October 24-25, 2008 Robert A. Sofferman, MD Professor

More information

Clinical Study Gender-Specific Variation in the Prognosis of Papillary Thyroid Cancer TNM Stages II to IV

Clinical Study Gender-Specific Variation in the Prognosis of Papillary Thyroid Cancer TNM Stages II to IV International Endocrinology Volume 2012, Article ID 379097, 5 pages doi:10.1155/2012/379097 Clinical Study Gender-Specific Variation in the Prognosis of Papillary Thyroid Cancer TNM Stages II to IV Sheng-Hwu

More information

Reoperative central neck surgery

Reoperative central neck surgery Reoperative central neck surgery R. Pandev, I. Tersiev, M. Belitova, A. Kouizi, D. Damyanov University Clinic of Surgery, Section Endocrine Surgery University Hospital Queen Johanna ISUL Medical University

More information

T here are four parathyroid glands, which are located

T here are four parathyroid glands, which are located 245 ORIGINAL ARTICLE Parathyroid invasion, nodal recurrence, and lung metastasis by papillary carcinoma of the thyroid K Kakudo, W Tang, Y Ito, Y Nakamura, H Yasuoka, S Morita, A Miyauchi... See end of

More information

유두상갑상선암종에서경부림프절전이의양상및치료

유두상갑상선암종에서경부림프절전이의양상및치료 KISEP Head and Neck Korean J Otolaryngol 2005;48:506- 유두상갑상선암종에서경부림프절전이의양상및치료 태경 전성하 이현창 김경래 이형석 박용수 2 안유헌 2 김태화 2 Pattern and Treatment of Papillary Thyroid Carcinoma with Cervical Lymph Node Metastasis

More information

Strategies for detection of recurrent disease in longterm follow-up of differentiated thyroid cancer

Strategies for detection of recurrent disease in longterm follow-up of differentiated thyroid cancer Strategies for detection of recurrent disease in longterm follow-up of differentiated thyroid cancer A rational approach to longterm follow-up based on dynamic risk assessment. World Congress on Thyroid

More information

PEDIATRIC Ariel Katz MD

PEDIATRIC Ariel Katz MD PEDIATRIC Ariel Katz MD Dept. Otolaryngology Head &Neck Surgery Wolfson Medical Center Holon, Israel OBJECTIVES Overview/Background Epidemiology/Etiology Intro to Guidelines Workup Treatment Follow-Up

More information

2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines

2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines 2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines Angela M. Leung, MD, MSc, ECNU November 5, 2016 Outline Workup of nontoxic thyroid nodule(s) Ultrasound FNAB Management of FNAB results

More information

Distant and Lymph Node Metastases of Thyroid Nodules with No Pathological Evidence of Malignancy: A Limitation of Pathological Examination

Distant and Lymph Node Metastases of Thyroid Nodules with No Pathological Evidence of Malignancy: A Limitation of Pathological Examination Endocrine Journal 2008, 55 (5), 889 894 Distant and Lymph Node Metastases of Thyroid Nodules with No Pathological Evidence of Malignancy: A Limitation of Pathological Examination YASUHIRO ITO, TOMONORI

More information

How good are we at finding nodules? Thyroid Nodules Thyroid Cancer Epidemiology Initial management Long-term follow up Disease-free status

How good are we at finding nodules? Thyroid Nodules Thyroid Cancer Epidemiology Initial management Long-term follow up Disease-free status New Perspectives in Thyroid Cancer Jennifer Sipos, MD Assistant Professor of Medicine Division of Endocrinology The Ohio State University Outline Thyroid Nodules Thyroid Cancer Epidemiology Initial management

More information

ORIGINAL ARTICLE. Management and Outcome of Recurrent Well-Differentiated Thyroid Carcinoma

ORIGINAL ARTICLE. Management and Outcome of Recurrent Well-Differentiated Thyroid Carcinoma ORIGINAL ARTICLE Management and Outcome of Recurrent Well-Differentiated Thyroid Carcinoma Carsten E. Palme, MBBS, FRACS; Zeeshan Waseem, BA; S. Naweed Raza, BSc; Spiro Eski, MD; Paul Walfish, MD, FRCPC;

More information

Pre-operative Ultrasound of Lymph Nodes in Thyroid Cancer

Pre-operative Ultrasound of Lymph Nodes in Thyroid Cancer Pre-operative Ultrasound of Lymph Nodes in Thyroid Cancer AACE - Advances in Medical and Surgical Management of Thyroid Cancer - 2018 Robert A. Levine, MD, FACE, ECNU Thyroid Center of New Hampshire Geisel

More information

Dr J K Jekel Dept. Surgery University of Pretoria

Dr J K Jekel Dept. Surgery University of Pretoria Dr J K Jekel Dept. Surgery University of Pretoria No Maybe ( T`s and C`s apply ) 1. Total thyroidectomy 2. Neck dissection only if nodes are involved 3. Ablative dose or doses of Radioactive Iodine 4.

More information

- RET/PTC rearrangement: 20% papillary thyroid cancer - RET: medullary thyroid cancer

- RET/PTC rearrangement: 20% papillary thyroid cancer - RET: medullary thyroid cancer Thyroid Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: 1. Lenvina is the first line therapy with powerful durable response and superior PFS in pts with RAI-refractory disease.

More information

Managing Thyroid Microcarcinomas

Managing Thyroid Microcarcinomas Review Article http://dx.doi.org/10.3349/ymj.2012.53.1.1 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 53(1):1-14, 2012 Managing Thyroid Microcarcinomas Ernest L. Mazzaferri Division of Endocrinology,

More information

Association between prognostic factors and clinical outcome of well-differentiated thyroid carcinoma: A retrospective 10-year follow-up study

Association between prognostic factors and clinical outcome of well-differentiated thyroid carcinoma: A retrospective 10-year follow-up study ONCOLOGY LETTERS 10: 1749-1754, 2015 Association between prognostic factors and clinical outcome of well-differentiated thyroid carcinoma: A retrospective 10-year follow-up study SHANGTONG LEI 1, ZIHAI

More information

A Review of Differentiated Thyroid Cancer

A Review of Differentiated Thyroid Cancer A Review of Differentiated Thyroid Cancer April 21 st, 2016 FPON Webcast Jonn Wu BMSc MD FRCPC Radiation Oncologist, Vancouver Centre Chair, Provincial H&N Tumour Group, BCCA Clinical Associate Professor,

More information

IN THE surgical management of

IN THE surgical management of ORIGINAL ARTICLE Papillary Thyroid Carcinoma Modified Radical Neck Dissection Improves Prognosis Shiro Noguchi, MD, PhD; Nobuo Murakami, MD; Hiroto Yamashita, MD, PhD; Masakatsu Toda, MD, PhD; Hitoshi

More information

Differentiated Thyroid Cancer: Reclassification of the Risk of Recurrence Based on the Response to Initial Treatment

Differentiated Thyroid Cancer: Reclassification of the Risk of Recurrence Based on the Response to Initial Treatment ORIGINAL ARTICLE Differentiated Thyroid Cancer: Reclassification of the Risk of Recurrence Based on the Response to Initial Treatment Martínez MP, Lozano Bullrich MP, Rey M, Ridruejo MC, Bomarito MJ, Claus

More information

Thyroid Nodule. Disclosure. Learning Objectives P A P A P A 3/18/2014. Nothing to disclose.

Thyroid Nodule. Disclosure. Learning Objectives P A P A P A 3/18/2014. Nothing to disclose. Thyroid Nodule Evaluating the patient with a thyroid nodule and some management options. Miguel V. Valdez PA C Disclosure Nothing to disclose. Learning Objectives Examination of thyroid gland Options for

More information

Pediatric Thyroid Cancer Lung Metastases. Liora Lazar MD

Pediatric Thyroid Cancer Lung Metastases. Liora Lazar MD Pediatric Thyroid Cancer Lung Metastases Liora Lazar MD Differentiated thyroid cancer (DTC) The 3rd most common solid tumor in childhood and adolescence Accounting for 1.5%-3% of all childhood cancers

More information

Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis

Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis Endocrine-Related Cancer (2005) 12 273 280 Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis T P Links, K M van Tol, P L Jager 1, J Th M Plukker 2, D A Piers 1, H

More information

Incidental versus clinically evident thyroid cancer: A 5-year follow-up study

Incidental versus clinically evident thyroid cancer: A 5-year follow-up study ORIGINAL ARTICLE Incidental versus clinically evident : A 5-year follow-up study Michele N. Minuto, MD, PhD, 1 * Mario Miccoli, DStat, 2 David Viola, MD, 3 Clara Ugolini, MD, PhD, 1 Riccardo Giannini,

More information

Surgical Treatment for Papillary Thyroid Carcinoma in Japan: Differences from Other Countries

Surgical Treatment for Papillary Thyroid Carcinoma in Japan: Differences from Other Countries REVIEW ARTICLE J Korean Thyroid Assoc Vol. 4, No. 2, November 2011 Surgical Treatment for Papillary Thyroid Carcinoma in Japan: Differences from Other Countries Yasuhiro Ito, MD and Akira Miyauchi, MD

More information

Research Article Papillary Thyroid Cancer, Macrofollicular Variant: The Follow-Up and Analysis of Prognosis of 5 Patients

Research Article Papillary Thyroid Cancer, Macrofollicular Variant: The Follow-Up and Analysis of Prognosis of 5 Patients yroid Research, Article ID 818134, 4 pages http://dx.doi.org/10.1155/2014/818134 Research Article Papillary Thyroid Cancer, Macrofollicular Variant: The Follow-Up and Analysis of Prognosis of 5 Patients

More information

Hong Kong SAR, China; 2 Department of Surgery, Division of Endocrine Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China

Hong Kong SAR, China; 2 Department of Surgery, Division of Endocrine Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China Ann Surg Oncol (2012) 19:3479 3485 DOI 10.1245/s10434-012-2391-6 ORIGINAL ARTICLE ENDOCRINE TUMORS Is There a Role for Unstimulated Thyroglobulin Velocity in Predicting Recurrence in Papillary Thyroid

More information

Research Article Therapeutic Outcomes of Patients with Multifocal Papillary Thyroid Microcarcinomas and Larger Tumors

Research Article Therapeutic Outcomes of Patients with Multifocal Papillary Thyroid Microcarcinomas and Larger Tumors Hindawi International Endocrinology Volume 2017, Article ID 4208178, 8 pages https://doi.org/10.1155/2017/4208178 Research Article Therapeutic Outcomes of Patients with Multifocal Papillary Thyroid Microcarcinomas

More information

Calcitonin. 1

Calcitonin.  1 Calcitonin Medullary thyroid carcinoma (MTC) is characterized by a high concentration of serum calcitonin. Routine measurement of serum calcitonin concentration has been advocated for detection of MTC

More information

Thyroid Nodules. Dr. HAKIMI, SpAK Dr. MELDA DELIANA, SpAK Dr. SISKA MAYASARI LUBIS, SpA

Thyroid Nodules. Dr. HAKIMI, SpAK Dr. MELDA DELIANA, SpAK Dr. SISKA MAYASARI LUBIS, SpA Thyroid Nodules ENDOCRINOLOGY DIVISION ENDOCRINOLOGY DIVISION Dr. HAKIMI, SpAK Dr. MELDA DELIANA, SpAK Dr. SISKA MAYASARI LUBIS, SpA Anatomical Considerations The Thyroid Nodule Congenital anomalies Thyroglossal

More information

American Head and Neck Society - Journal Club Volume 22, July 2018

American Head and Neck Society - Journal Club Volume 22, July 2018 - Table of Contents click the page number to go to the summary and full article link. Location and Causation of Residual Lymph Node Metastasis After Surgical Treatment of Regionally Advanced Differentiated

More information

Clinical Study Analysis of Clinical Outcome of Patients with Poorly Differentiated Thyroid Carcinoma

Clinical Study Analysis of Clinical Outcome of Patients with Poorly Differentiated Thyroid Carcinoma International Scholarly Research Network ISRN Endocrinology Volume 2011, Article ID 308029, 5 pages doi:10.5402/2011/308029 Clinical Study Analysis of Clinical Outcome of Patients with Poorly Differentiated

More information

THYROID CANCER IN CHILDREN. Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine

THYROID CANCER IN CHILDREN. Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine THYROID CANCER IN CHILDREN Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine Thyroid nodules Rare Female predominance 4-fold as likely to be malignant Hx Radiation exposure?

More information

THYROID CANCER IN CHILDREN

THYROID CANCER IN CHILDREN THYROID CANCER IN CHILDREN Isabel ROCA, Montserrat NEGRE Joan CASTELL HU VALL HEBRON BARCELONA EPIDEMIOLOGY ADULTS males 1,2-2,6 cases /100.000 females 2,0-3,8 cases /100.000 0,02-0,3 / 100.000 children

More information

International Czech and Slovak cooperation in the treatment of patients with differentiated thyroid cancer

International Czech and Slovak cooperation in the treatment of patients with differentiated thyroid cancer Nuclear Medicine Review 2006 Vol. 9, No. 1, pp. 84 88 Copyright 2006 Via Medica ISSN 1506 9680 International Czech and Slovak cooperation in the treatment of patients with differentiated thyroid cancer

More information

What you need to know about Thyroid Cancer

What you need to know about Thyroid Cancer What you need to know about Thyroid Cancer This booklet has been designed to help you to learn more about your thyroid cancer. It covers the most important areas and answers some of the frequently asked

More information

Advances in the management of thyroid cancer

Advances in the management of thyroid cancer International Journal of Surgery (2005) 3, 213e220 www.int-journal-surgery.com REVIEW Advances in the management of thyroid cancer Ashok R. Shaha* Memorial Sloan-Kettering Cancer Center, 1275 York Avenue,

More information

Thyroid remnant volume and Radioiodine ablation in Differentiated thyroid carcinoma.

Thyroid remnant volume and Radioiodine ablation in Differentiated thyroid carcinoma. ORIGINAL ARTICLE Thyroid remnant volume and Radioiodine ablation in Differentiated thyroid carcinoma. Md. Sayedur Rahman Miah, Md. Reajul Islam, Tanjim Siddika Institute of Nuclear Medicine & Allied Sciences,

More information

Oncological outcomes for patients with well differentiated thyroid cancer Nixon, I.J.

Oncological outcomes for patients with well differentiated thyroid cancer Nixon, I.J. UvA-DARE (Digital Academic Repository) Oncological outcomes for patients with well differentiated thyroid cancer Nixon, I.J. Link to publication Citation for published version (APA): Nixon, I. J. (2013).

More information

Thyroid Pathology: It starts and ends with the gross. Causes of Thyrophobia. Agenda. Diagnostic ambiguity. Treatment/prognosis disconnect

Thyroid Pathology: It starts and ends with the gross. Causes of Thyrophobia. Agenda. Diagnostic ambiguity. Treatment/prognosis disconnect Thyroid Pathology: It starts and ends with the gross Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University of Arkansas for

More information

Long Term Follow-Up for Differentiated Thyroid Cancer: The Mayo Experience

Long Term Follow-Up for Differentiated Thyroid Cancer: The Mayo Experience Long Term Follow-Up for Differentiated Thyroid Cancer: The Mayo Experience Geoffrey B. Thompson, MD Professor of Surgery College of Medicine, Mayo Clinic Differentiated Thyroid Cancer Objectives Overview

More information

Get The Cancer Staging Manual Pdf Thyroid

Get The Cancer Staging Manual Pdf Thyroid Get The Cancer Staging Manual Pdf Thyroid Most people with thyroid cancer have no known risk factors that they can change, Manual. They are based on the stage of the cancer when the person is first. Staging

More information

Perigastric lymph node metastases in gastric cancer: comparison of different staging systems

Perigastric lymph node metastases in gastric cancer: comparison of different staging systems Gastric Cancer (1999) 2: 201 205 Original article 1999 by International and Japanese Gastric Cancer Associations Perigastric lymph node metastases in gastric cancer: comparison of different staging systems

More information

Multi-Organ Distant Metastases in Follicular Thyroid Cancer- Rare Case Report

Multi-Organ Distant Metastases in Follicular Thyroid Cancer- Rare Case Report Multi-Organ Distant Metastases in Follicular Thyroid Cancer- Rare Case Report Dr. Mohammed Raza 1, Dr. Sindhuri K 2, Dr. Dinesh Reddy Y 3 1 Professor, Department of Surgery, JSS University, Mysore, India

More information

Correspondence should be addressed to Stan H. M. Van Uum;

Correspondence should be addressed to Stan H. M. Van Uum; Oncology Volume 2016, Article ID 6496750, 6 pages http://dx.doi.org/10.1155/2016/6496750 Research Article Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive

More information

Prognostic value of the 8 th tumor-node-metastasis classification for follicular carcinoma and poorly differentiated carcinoma of the thyroid in Japan

Prognostic value of the 8 th tumor-node-metastasis classification for follicular carcinoma and poorly differentiated carcinoma of the thyroid in Japan 2018, 65 (6), 621-627 ORIGINAL Prognostic value of the 8 th tumor-node-metastasis classification for follicular carcinoma and poorly differentiated carcinoma of the thyroid in Japan Yasuhiro Ito 1), Akira

More information

Carcinoma of thyroid - clinical presentation and outcome

Carcinoma of thyroid - clinical presentation and outcome Med. J. Malaysia Vol. 46 No. 3 September 1991 Carcinoma of thyroid - clinical presentation and outcome K. Sothy, MBBS M. Mafauzy, MBBS, MRCP, M.Med. Sci. W.B. Wan Mohamad, MD, MRCP B.E. Mustaffa, MBBS,

More information

Reevaluating the prognostic significance of male gender for papillary thyroid carcinoma and microcarcinoma: a SEER database analysis

Reevaluating the prognostic significance of male gender for papillary thyroid carcinoma and microcarcinoma: a SEER database analysis www.nature.com/scientificreports Received: 1 May 2017 Accepted: 30 August 2017 Published: xx xx xxxx OPEN Reevaluating the prognostic significance of male gender for papillary thyroid carcinoma and microcarcinoma:

More information

Diagnostic 131 I whole body scanning after thyroidectomy and ablation for differentiated thyroid cancer

Diagnostic 131 I whole body scanning after thyroidectomy and ablation for differentiated thyroid cancer European Journal of Endocrinology (2004) 150 649 653 ISSN 0804-4643 CLINICAL STUDY Diagnostic 131 I whole body scanning after thyroidectomy and ablation for differentiated thyroid cancer Henry Taylor,

More information

42 yr old male with h/o Graves disease and prior I 131 treatment presents with hyperthyroidism and undetectable TSH. 2 hr uptake 20%, 24 hr uptake 50%

42 yr old male with h/o Graves disease and prior I 131 treatment presents with hyperthyroidism and undetectable TSH. 2 hr uptake 20%, 24 hr uptake 50% Pinhole images of the neck are acquired in multiple projections, 24hrs after the oral administration of approximately 200 µci of I123. Usually, 24hr uptake value if also calculated (normal 24 hr uptake

More information

Prognostic Evaluation of Patients With Multicentric Papillary Thyroid Microcarcinoma

Prognostic Evaluation of Patients With Multicentric Papillary Thyroid Microcarcinoma Volume 110 Number 8 August 2011 Formosan Medical Association Taipei, Taiwan ISSN 0929 6646 Resveratrol for prophylaxis of ischemic stroke Microglia and chronic pain ART in HIV-1-discordant couples in Taiwan

More information

Role of Radio-Iodine Ablation According to Risk Stratification in Well Differentiated Thyroid Cancer

Role of Radio-Iodine Ablation According to Risk Stratification in Well Differentiated Thyroid Cancer Journal of the Egyptian Nat. Cancer Inst., Vol. 13, No. 1, March: 6369, 2001 Role of RadioIodine Ablation According to Risk Stratification in Well Differentiated Thyroid Cancer HOSNA MOUSTAFA, M.D.*; SHEREEN

More information

Biomedical Research 2017; 28 (21): ISSN X

Biomedical Research 2017; 28 (21): ISSN X Biomedical Research 2017; 28 (21): 9497-9501 ISSN 0970-938X www.biomedres.info Analysis of relevant risk factor and recurrence prediction model construction of thyroid cancer after surgery. Shuai Lin 1#,

More information

Treatment of Cervical Lymph Node Metastases Differentiated Thyroid Cancer

Treatment of Cervical Lymph Node Metastases Differentiated Thyroid Cancer Treatment of Cervical Lymph Node Metastases Differentiated Thyroid Cancer Well Differentiated Thyroid Cancer Natural History and Prognosis EORTC AGES AMES MACIS QuickTime and a TIFF (LZW) decompressor

More information

Management of Recurrent Thyroid Cancer

Management of Recurrent Thyroid Cancer Management of Recurrent Thyroid Cancer Eric Genden, MD, MHA Isidore Professor and Chairman Department of Otolaryngology- Head and Neck Surgery Senior Associate Dean for Clinical Affairs The Icahn School

More information

Lymphovascular Invasion is Associated with Survival for Papillary Thyroid Cancer

Lymphovascular Invasion is Associated with Survival for Papillary Thyroid Cancer Page 1 of 21 Accepted Preprint first posted on 17 June 2016 as Manuscript ERC-16-0123 1 2 3 4 5 6 7 8 9 10 Title Lymphovascular Invasion is Associated with Survival for Papillary Thyroid Cancer Authors

More information

Dynamic Risk Stratification:

Dynamic Risk Stratification: Dynamic Risk Stratification: Using Risk Estimates to Guide Initial Management R Michael Tuttle, MD Clinical Director, Endocrinology Service Memorial Sloan Kettering Cancer Center Professor of Medicine

More information

PAPILLARY THYROID CANCER IS A

PAPILLARY THYROID CANCER IS A ORIGINAL ARTICLE Thyroid Cancer Survival in the United States Observational Data From 1973 to 2005 Louise Davies, MD, MS; H. Gilbert Welch, MD, MPH Objective: To compare the survival rate of people with

More information

Shifting Paradigms and Debates in the Management of Well-differentiated Thyroid Cancer

Shifting Paradigms and Debates in the Management of Well-differentiated Thyroid Cancer DEBATE WJOES Shifting Paradigms and Debates in the Management of Well-differentiated Thyroid Cancer Shifting Paradigms and Debates in the Management of Well-differentiated Thyroid Cancer Ashok R Shaha

More information

I-131 ABLATION AND ADJUVANT THERAPY OF THYROID CANCER

I-131 ABLATION AND ADJUVANT THERAPY OF THYROID CANCER AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Advances in Medical and Surgical Management of Thyroid Cancer January 23-24, 2015 I-131 ABLATION AND ADJUVANT THERAPY OF THYROID CANCER 2015 Leonard Wartofsky,

More information

Initial surgery for differentiated thyroid cancer: What is the appropriate extent and attendant risks and benefits?

Initial surgery for differentiated thyroid cancer: What is the appropriate extent and attendant risks and benefits? Initial surgery for differentiated thyroid cancer: What is the appropriate extent and attendant risks and benefits? Julie Ann Sosa, MD MA FACS Professor of Surgery and Medicine Chief, Section of Endocrine

More information

Oncological outcomes for patients with well differentiated thyroid cancer Nixon, I.J.

Oncological outcomes for patients with well differentiated thyroid cancer Nixon, I.J. UvA-DARE (Digital Academic Repository) Oncological outcomes for patients with well differentiated thyroid cancer Nixon, I.J. Link to publication Citation for published version (APA): Nixon, I. J. (2013).

More information

Endocrine, Original Article The Impact of Thyroid Stunning on Radioactive Iodine Ablation Compared to Other Risk Factors

Endocrine, Original Article The Impact of Thyroid Stunning on Radioactive Iodine Ablation Compared to Other Risk Factors 68 Endocrine, Original Article The Impact of Thyroid Stunning on Radioactive Iodine Ablation Compared to Other Risk Factors Abd El-Kareem, M *, El-Refaie, SH *, Zaher, A **, Abo-Gaba, Ml * and Abdo, S

More information

Differentiated Thyroid Carcinoma

Differentiated Thyroid Carcinoma Differentiated Thyroid Carcinoma The GOOD cancer? Jennifer Sipos, MD Associate Professor of Medicine Director, Benign Thyroid Program Division of Endocrinology, Diabetes and Metabolism The Ohio State University

More information

ORIGINAL ARTICLE. Follicular Variant of Papillary Thyroid Carcinoma

ORIGINAL ARTICLE. Follicular Variant of Papillary Thyroid Carcinoma Follicular Variant of Papillary Thyroid Carcinoma A Long-term Follow-up ORIGINAL ARTICLE Christian Passler, MD; Gerhard Prager, MD; Christian Scheuba, MD; Barbara E. Niederle, MD; Klaus Kaserer, MD; Georg

More information

RESEARCH ARTICLE. Comparison of Presentation and Clinical Outcome between Children and Young Adults with Differentiated Thyroid Cancer

RESEARCH ARTICLE. Comparison of Presentation and Clinical Outcome between Children and Young Adults with Differentiated Thyroid Cancer RESEARCH ARTICLE Comparison of Presentation and Clinical Outcome between Children and Young Adults with Jian-Tao Wang 1,2&, Rui Huang 1&, An-Ren Kuang 1 * Abstract Background: The aim of the present study

More information

Thyroid. At-A-Glance. Papillary or follicular (differentiated) UNDER 45 YEARS Stage I Any T Any N M0 Stage II Any T Any N M1

Thyroid. At-A-Glance. Papillary or follicular (differentiated) UNDER 45 YEARS Stage I Any T Any N M0 Stage II Any T Any N M1 8 Thyroid At-A-Glance S U M M A R Y O F C H A N G E S Tumor staging (T1) has been subdivided into T1a ( 1 cm) and T1b ( 1 2 cm) limited to thyroid The descriptors to subdivide T categories have been changed

More information

ORIGINAL ARTICLE. Influence of Previous Radiation Exposure on Pathologic Features and Clinical Outcome in Patients With Thyroid Cancer

ORIGINAL ARTICLE. Influence of Previous Radiation Exposure on Pathologic Features and Clinical Outcome in Patients With Thyroid Cancer ORIGINAL ARTICLE Influence of Previous Radiation Exposure on Pathologic Features and Clinical Outcome in Patients With Thyroid Cancer Raewyn M. Seaberg, MD, PhD; Spiro Eski, MD; Jeremy L. Freeman, MD,

More information

Thyroid Gland. Protocol applies to all malignant tumors of the thyroid gland, except lymphomas.

Thyroid Gland. Protocol applies to all malignant tumors of the thyroid gland, except lymphomas. Thyroid Gland Protocol applies to all malignant tumors of the thyroid gland, except lymphomas. Procedures Cytology (No Accompanying Checklist) Partial Thyroidectomy Total Thyroidectomy With/Without Lymph

More information

Review Article Thyroidectomy and Lymph Node Dissection in Papillary Thyroid Carcinoma

Review Article Thyroidectomy and Lymph Node Dissection in Papillary Thyroid Carcinoma SAGE-Hindawi Access to Research Thyroid Research Volume 2011, Article ID 634170, 6 pages doi:10.4061/2011/634170 Review Article Thyroidectomy and Lymph Node Dissection in Papillary Thyroid Carcinoma Yasuhiro

More information

New York, the nation s thyroid gland. Christopher Morley ( ), "Shore Leave"

New York, the nation s thyroid gland. Christopher Morley ( ), Shore Leave New York, the nation s thyroid gland Christopher Morley (1890-1957), "Shore Leave" Thyroid Literature Medline Thyroid disease 136,053 Thyroid tumors 33,554 New Paper on Thyroid Disease Every 3 Hours New

More information

Clinical Guidance in Thyroid Cancers. Stephen Robinson Imperial at St Mary s On behalf of BTA

Clinical Guidance in Thyroid Cancers. Stephen Robinson Imperial at St Mary s On behalf of BTA Clinical Guidance in Thyroid Cancers Stephen Robinson Imperial at St Mary s On behalf of BTA Background to thyroid cancer Incidence probably increasing slowly 1971-95; 2.3 women 0.9 men /100,000 2001;

More information

Thyroid INTRODUCTION ANATOMY SUMMARY OF CHANGES

Thyroid INTRODUCTION ANATOMY SUMMARY OF CHANGES AJC 7/14/06 1:19 PM Page 67 Thyroid C73.9 Thyroid gland SUMMARY OF CHANGES Tumor staging (T) has been revised and the categories redefined. T4 is now divided into T4a and T4b. Nodal staging (N) has been

More information

Metastatic lymph node status in the central compartment of papillary thyroid carcinoma: A prognostic factor of locoregional recurrence

Metastatic lymph node status in the central compartment of papillary thyroid carcinoma: A prognostic factor of locoregional recurrence ORIGINAL ARTICLE Metastatic lymph node status in the central compartment of papillary thyroid carcinoma: A prognostic factor of locoregional recurrence Young Min Park, MD, PhD, 1 Soo-Geun Wang, MD, PhD,

More information

Staging Systems for Differentiated Thyroid Carcinomas

Staging Systems for Differentiated Thyroid Carcinomas Staging Systems for Differentiated Thyroid Carcinomas 6 Ronnie Meiyi Wong and Glenn D. Braunstein Introduction A multitude of retrospective studies have identified prognostic factors for the mortality

More information

Differentiated thyroid carcinoma (DTC) is one of the

Differentiated thyroid carcinoma (DTC) is one of the Delayed Initial Radioactive Iodine Therapy Resulted in Poor Survival in Patients with Metastatic Differentiated Thyroid Carcinoma: A Retrospective Statistical Analysis of 198 Cases Tatsuya Higashi 1,2,

More information

Disclosures Nodal Management in Differentiated Thyroid Carcinoma

Disclosures Nodal Management in Differentiated Thyroid Carcinoma Disclosures Nodal Management in Differentiated Thyroid Carcinoma Nothing to disclose Jonathan George, MD, MPH Assistant Professor UCSF Head and Neck Oncologic & Endocrine Surgery Objectives Overview Describe

More information

B. Environmental Factors. a. The major risk factor to papillary thyroid cancer is exposure to ionizing radiation, during the first 2 decades of life.

B. Environmental Factors. a. The major risk factor to papillary thyroid cancer is exposure to ionizing radiation, during the first 2 decades of life. B. Environmental Factors. a. The major risk factor to papillary thyroid cancer is exposure to ionizing radiation, during the first 2 decades of life. b. Deficiency of dietary iodine: - Is linked with a

More information

Papillary Thyroid Microcarcinoma Presenting as Horner s Syndrome: A Novel Clinical Presentation

Papillary Thyroid Microcarcinoma Presenting as Horner s Syndrome: A Novel Clinical Presentation Case Report American Journal of Cancer Case Reports http://ivyunion.org/index.php/ajccr/ Page 1 of 6 Papillary Thyroid Microcarcinoma Presenting as Horner s Syndrome: A Novel Clinical Presentation Ammara

More information

Correlation analyses of thyroid-stimulating hormone and thyroid autoantibodies with differentiated thyroid cancer

Correlation analyses of thyroid-stimulating hormone and thyroid autoantibodies with differentiated thyroid cancer JBUON 2018; 23(5): 1467-1471 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Correlation analyses of thyroid-stimulating hormone and thyroid autoantibodies

More information